- Messages
- 1,961
- Location
- Undisclosed
Will receive second dose of vaccine later this morning.
Not to worry, since as previously noted, zombies eat brains so most of you (Cons/Trumptards/religious nutballs) will be safe.
New findings - 2 dose vaccines effective for over 6 months (at least) and also against the UK and S Africa variants.
You anti-vaxers, quit being silly and reckless. Vaccines will shortly be available to all. Go get it. Stop jeopardizing other people's lives and prolonging/facilitating the spread of theCovids and developement of new variants.
Pfizer () and BioNTech's () COVID-19 vaccine is proving effective six months after the second dose, according to an ongoing analysis of the Phase 3 trial participants.
The vaccine showed 91.3% efficacy against COVID-19, slightly lower than the original 95% seen in Phase 3 trials.
The data, from 12,000 of the more than 44,000 adults in the trial, is a result of observations from seven days through six months after the second dose was received.
The two companies announced the results in a statement Thursday, with plans to provide the detailed data to global regulatory bodies, including the U.S. Food and Drug Administration (FDA).
Of note was the vaccine's efficacy in South Africa, where the B.1.351 variant originated. Among the more dominant strains globally, the B.1.351 has shown the most reduction in vaccine efficacies both in Phase 3 trials and in labs.
The Pfizer/BioNTech was 100% effective in preventing COVID-19 cases in South Africa, according to the companies.
Not to worry, since as previously noted, zombies eat brains so most of you (Cons/Trumptards/religious nutballs) will be safe.
New findings - 2 dose vaccines effective for over 6 months (at least) and also against the UK and S Africa variants.
You anti-vaxers, quit being silly and reckless. Vaccines will shortly be available to all. Go get it. Stop jeopardizing other people's lives and prolonging/facilitating the spread of theCovids and developement of new variants.
Pfizer () and BioNTech's () COVID-19 vaccine is proving effective six months after the second dose, according to an ongoing analysis of the Phase 3 trial participants.
The vaccine showed 91.3% efficacy against COVID-19, slightly lower than the original 95% seen in Phase 3 trials.
The data, from 12,000 of the more than 44,000 adults in the trial, is a result of observations from seven days through six months after the second dose was received.
The two companies announced the results in a statement Thursday, with plans to provide the detailed data to global regulatory bodies, including the U.S. Food and Drug Administration (FDA).
Of note was the vaccine's efficacy in South Africa, where the B.1.351 variant originated. Among the more dominant strains globally, the B.1.351 has shown the most reduction in vaccine efficacies both in Phase 3 trials and in labs.
The Pfizer/BioNTech was 100% effective in preventing COVID-19 cases in South Africa, according to the companies.
